PL
Panacea Life Sciences Holdings, Inc.
PLSH · OTC
$0.09 +17.24% (+$0.01)
1M -13.97%
Market Cap $1.80M
P/E Ratio -
Div. Yield -
ROE 145.76%
Bulios Fair Price
$0.04
52.9% downside
Current Price
$0.085
Undervalued Fair Value Overvalued
According to Bulios Fair Price, PLSH is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Moderate
4/9Valuation
81 /100
Cheap P/S 6.83x
P/FCF 3.93x
P/B 1.64x
Growth
0 /100
Declining Rev. growth 17.59%
EPS growth N/A
Book val. growth N/A
Profitability
30 /100
Weak Gross margin 612.89%
FCF margin 173.90%
Net margin 2,147.67%
Quality
3 /100
Poor ROIC 59.37%
Asset turnover 0.20x
ROE 145.76%
Debt
69 /100
Low Debt/Equity 0.17x
Int. coverage -20.36x
Current ratio 2.30x
Stability
21 /100
Unstable Beta 2.55x
Profitable years 0
Rev. volatility 80.27%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about PLSH
Online
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Leslie A. Buttorff
Employees
3
Headquarters
Greenwood Village